论文信息 - A pharmacokinetically (PK) and pharmacodynamically (PD) driven phase I trial of the pan-AKT inhibitor AZD5363 with expansion cohorts in PIK3CA mutant breast and gynecological cancers. - 字舞流文

A pharmacokinetically (PK) and pharmacodynamically (PD) driven phase I trial of the pan-AKT inhibitor AZD5363 with expansion cohorts in PIK3CA mutant breast and gynecological cancers.

J. Schellens | P. Elvin | G. Batist | U. Banerji | P. Bedard | P. Kabos | B. Davies | S. Westin | P. Lawrence | J. Pérez-Fidalgo | J. Yates | E. Dean | J. Lindemann | P. Rugman | B. You | H. Ambrose | A. Foxley | E. Casson | S. Salim